Rankings
▼
Calendar
KROS FY 2021 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
KROS
Keros Therapeutics, Inc.
$414M
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$20M
Gross Profit
$20M
100.0% margin
Operating Income
-$56M
-280.5% margin
Net Income
-$59M
-292.3% margin
EPS (Diluted)
$-2.52
Cash Flow
Operating Cash Flow
-$62M
Free Cash Flow
-$63M
Stock-Based Comp.
$12M
Balance Sheet
Total Assets
$255M
Total Liabilities
$12M
Stockholders' Equity
$243M
Cash & Equivalents
$230M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$20M
$0
—
Gross Profit
$20M
-$605,000
+3422.3%
Operating Income
-$56M
-$47M
-20.8%
Net Income
-$59M
-$45M
-29.5%
← Q4 2020
All Quarters
Q1 2021 →